Related Experiment Videos
Anticoagulation in dilated cardiomyopathy
1Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, USA.
Insights
Patients with dilated cardiomyopathy face high risks of thromboembolic events. A national registry may offer practical insights into anticoagulation effectiveness and bleeding risks, avoiding a large clinical trial.
Area of Science:
- Cardiology
- Thrombosis
- Pharmacology
Background:
- Patients with dilated cardiomyopathy (DCM) exhibit numerous risk factors for thromboembolic events.
- Existing data on the incidence of these events in DCM patients is highly variable.
- There is a lack of controlled studies evaluating long-term anticoagulation in DCM with congestive heart failure.
Purpose of the Study:
- To review existing literature on thromboembolic event risks in dilated cardiomyopathy.
- To assess the efficacy and safety of anticoagulation therapy in this patient group.
- To propose an alternative data collection strategy for evaluating anticoagulation in DCM.
Main Methods:
- Systematic review of published data on thromboembolic events in dilated cardiomyopathy.
- Analysis of reported effectiveness and risks associated with anticoagulation.
- Proposal for a national registry to collect observational data.
Main Results:
- The incidence of thromboembolic events in dilated cardiomyopathy patients varies significantly across studies.
- Anticoagulation's role in reducing these events and its associated bleeding risks require further clarification.
- A national registry is suggested as a feasible method to gather comprehensive data.
Conclusions:
- Further research is needed to establish optimal anticoagulation strategies for dilated cardiomyopathy.
- A national registry offers a practical approach to collecting crucial data on thromboembolism and bleeding.
- Observational data from a registry can inform clinical practice regarding anticoagulation in DCM.
Abstract:
Patients with dilated cardiomyopathy have multiple factors that predispose to thromboembolic events. However, reports of the incidence of thromboembolic events in this population vary widely. There has never been a controlled study of long-term anticoagulation among patients with congestive heart failure due to dilated cardiomyopathy. In this report we review the available published data regarding the risk of thromboembolic events in patients with dilated cardiomyopathy, and the effectiveness and risks of anticoagulation in this population. Although many investigators have called for a prospective, randomized clinical trial to assess the risks and benefits of long-term anticoagulation in patients with dilated cardiomyopathy, a more practical approach may be to compile a national registry of patients with dilated cardiomyopathy to collect observational data on both the rate of embolic events as well as bleeding complications among patients with and without anticoagulation.